放射線皮膚炎:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC9948IDB)
◆英語タイトル:Radiodermatitis - Pipeline Review, H2 2017
◆商品コード:GMDHC9948IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年11月30日
◆ページ数:34
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における放射線皮膚炎の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・放射線皮膚炎の概要
・放射線皮膚炎治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・放射線皮膚炎パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・放射線皮膚炎治療薬開発に取り組んでいる企業:企業別製品パイプライン
・放射線皮膚炎治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Radiodermatitis – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis – Pipeline Review, H2 2017, provides an overview of the Radiodermatitis (Toxicology) pipeline landscape.

Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients’ skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiodermatitis (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiodermatitis (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Toxicology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Radiodermatitis – Overview 6
Radiodermatitis – Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Radiodermatitis – Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Radiodermatitis – Companies Involved in Therapeutics Development 20
Daiichi Sankyo Co Ltd 20
FirstString Research Inc 20
Foresee Pharmaceuticals LLC 20
SK Chemicals Co Ltd 21
viDA Therapeutics Inc 21
Radiodermatitis – Drug Profiles 22
cerium oxide – Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
FP-045 – Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Granexin – Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
phenylbutyrate – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
RS-9 – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
SKI-2162 – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
VTI-1000 Series – Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
ZM-241385 – Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Radiodermatitis – Dormant Projects 31
Radiodermatitis – Discontinued Products 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Number of Products under Development for Radiodermatitis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Radiodermatitis - Pipeline by Daiichi Sankyo Co Ltd, H2 2017 20
Radiodermatitis - Pipeline by FirstString Research Inc, H2 2017 20
Radiodermatitis - Pipeline by Foresee Pharmaceuticals LLC, H2 2017 21
Radiodermatitis - Pipeline by SK Chemicals Co Ltd, H2 2017 21
Radiodermatitis - Pipeline by viDA Therapeutics Inc, H2 2017 21
Radiodermatitis - Dormant Projects, H2 2017 31
Radiodermatitis - Discontinued Products, H2 2017 32

List of Figures
Number of Products under Development for Radiodermatitis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Targets, H2 2017 12
Number of Products by Stage and Targets, H2 2017 12
Number of Products by Mechanism of Actions, H2 2017 14
Number of Products by Stage and Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

【レポートのキーワード】

放射線皮膚炎

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 放射線皮膚炎:治療薬開発パイプライン分析(Radiodermatitis - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆